News and EventsNews Xinnate får FDAs Fast Track-status för TCP-25 vid behandling av epidermolysis bullosa10 June, 2026 Xinnate receives FDA Fast Track Designation for TCP-25 for the Treatment of Epidermolysis Bullosa10 June, 2026 Xinnate granted patent in Japan for TCP-25 formulation. The patent further strengthens the global intellectual property protection of the TCP-25 gel.18 February, 2026 Xinnate AB har fått patent godkänt i Japan avseende formulering av TCP-25. Patentet är innebär ett ytterligare stärkt globalt immateriellt skydd för TCP-25 gelen.18 February, 2026 Xinnate announces that recruitment has started and the first patient has been included in the STEP study with TCP-2530 January, 2026 Xinnate meddelar att rekryteringen har startat och första patienten har blivit inkluderad i STEP-studien med TCP-2530 January, 2026 First Scientific Publication Reporting Clinical Trial Results for Xinnate’s Proprietary Drug Candidate TCP-2522 December, 2025 Xinnate Completes Oversubscribed Share Issue of SEK 38,5m18 December, 2025 Xinnate Receives FDA IND Approval for TCP-25, Enabling Pivotal Phase 2/3 STEP Study in Epidermolysis Bullosa10 December, 2025 Xinnate raises SEK 31 million in oversubscribed share issue1 July, 2025 ALL NEWSEvents The 3rd World Congress on Rare Skin Diseases: 01-03 July 2026 BIO International Convention: 22-25 June 2026 EADV Symposium 2026: 07-09 May 2026 EB 2026: 20-22 Jan 2026 EB Awareness week: 25-31 Oct 2025 NLS Days: 13-14 Oct 2025 ESDR MEETING: 10-13 Sep 2025 ALL EVENTSPress Releases Xinnate får FDAs Fast Track-status för TCP-25 vid behandling av epidermolysis bullosa10 June, 2026 Xinnate receives FDA Fast Track Designation for TCP-25 for the Treatment of Epidermolysis Bullosa10 June, 2026 Xinnate announces that recruitment has started and the first patient has been included in the STEP study with TCP-2530 January, 2026 Xinnate meddelar att rekryteringen har startat och första patienten har blivit inkluderad i STEP-studien med TCP-2530 January, 2026 First Scientific Publication Reporting Clinical Trial Results for Xinnate’s Proprietary Drug Candidate TCP-2522 December, 2025 Xinnate Completes Oversubscribed Share Issue of SEK 38,5m18 December, 2025 Xinnate Receives FDA IND Approval for TCP-25, Enabling Pivotal Phase 2/3 STEP Study in Epidermolysis Bullosa10 December, 2025 ALL PRESS RELEASES
